ResMed Inc (RSMDF) shareholders
RSMDFOTCSurgical & Medical Instruments & ApparatusFiscal year ends June 30Also trades as RMD
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 13, 2026Score 21/3011% below fair value
$22.61+0.00 (0.00%)
Close on Oct 19, 2026Market cap $33.17BP/E 22.0Yield 1.04%
Ownership
Who owns ResMed's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
0 buys · 30 sales
Net sold $21.13M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 12,783,715 | 8.70% | 13G (passive) amendment | Dec 31, 2023 |
| Vanguard Capital Management | 11,961,706 | 8.21% | 13G (passive) | Mar 31, 2026 |
| AustralianSuper Pty Ltd | 8,276,381 | 5.70% | 13G (passive) | Jun 30, 2026 |
| Vanguard Portfolio Management | 7,886,489 | 5.41% | 13G (passive) | Mar 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| Michael J. Farrell | Chairman and CEO, Director | 468,346 | Sep 10, 2026 |
| Michael J. Rider | Global General Counsel | 9,488 | Jun 3, 2026 |
| Brett Sandercock | Chief Financial Officer | 83,495 | May 4, 2026 |
| Aaron Bloomer | Chief Financial Officer | – | May 4, 2026 |
| Justin Leong | Chief Product Officer | 29,028 | Nov 24, 2025 |
| Kaushik Ghoshal | Chief Commercial Officer, SaaS | 19,430 | Aug 5, 2025 |
| Peter C. Farrell | Director | 1,095,977 | Sep 4, 2026 |
| Witte Jan De | Director | 4,261 | Nov 26, 2025 |
| Nicole Mowad-Nassar | Director | 777 | Nov 26, 2025 |
| Karen Drexler | Director | 10,602 | Nov 24, 2025 |
| Christopher DelOrefice | Director | 2,423 | Nov 24, 2025 |
| Carol Burt | Director | 18,816 | Nov 24, 2025 |
| John Hernandez | Director | 5,118 | Nov 24, 2025 |
| Desney Tan | Director | 6,002 | Nov 24, 2025 |
| Ronald R. Taylor | Director | 24,771 | Nov 24, 2025 |
| Harjit Gill | Director | 10,940 | Nov 24, 2025 |
| Richard Sulpizio | Director | 17,796 | Nov 21, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael J. Farrell Chairman and CEO, Director | Sep 8, 2026 | Sale(10b5-1 plan) | −4,991 | $222.44 | $1.11M | 466,256 |
| Michael J. Farrell Chairman and CEO, Director | Sep 8, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,247 |
| Peter C. Farrell Director | Sep 2, 2026 | Sale(10b5-1 plan) | −970 | $234.73 | $227.69K | 51,803 |
| Michael J. Farrell Chairman and CEO, Director | Aug 7, 2026 | Sale(10b5-1 plan) | −4,991 | $205.69 | $1.03M | 466,256 |
| Michael J. Farrell Chairman and CEO, Director | Aug 7, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,247 |
| Peter C. Farrell Director | Aug 5, 2026 | Sale(10b5-1 plan) | −8,000 | $225.00 | $1.80M | 52,773 |
| Michael J. Farrell Chairman and CEO, Director | Jul 7, 2026 | Sale(10b5-1 plan) | −4,991 | $218.55 | $1.09M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | Jul 7, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Michael J. Farrell Chairman and CEO, Director | Jun 8, 2026 | Sale(10b5-1 plan) | −4,991 | $193.96 | $968.05K | 466,256 |
| Michael J. Farrell Chairman and CEO, Director | Jun 8, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Michael J. Rider Global General Counsel | Jun 1, 2026 | Tax withholding | −268.74 | $190.57 | $51.21K | 9,488 |
| Michael J. Farrell Chairman and CEO, Director | May 7, 2026 | Sale(10b5-1 plan) | −4,991 | $207.82 | $1.04M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | May 7, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Michael J. Farrell Chairman and CEO, Director | Apr 7, 2026 | Sale(10b5-1 plan) | −4,991 | $225.50 | $1.13M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | Apr 7, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Brett Sandercock Chief Financial Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −1,000 | $224.31 | $224.31K | 83,495 |
| Peter C. Farrell Director | Apr 1, 2026 | Sale(10b5-1 plan) | −2,000 | $225.00 | $450.00K | 60,773 |
| Michael J. Farrell Chairman and CEO, Director | Mar 9, 2026 | Sale(10b5-1 plan) | −4,991 | $251.03 | $1.25M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | Mar 9, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Peter C. Farrell Director | Mar 4, 2026 | Sale(10b5-1 plan) | −2,000 | $260.22 | $520.44K | 62,773 |
| Brett Sandercock Chief Financial Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −1,000 | $254.30 | $254.30K | 84,495 |
| Michael J. Farrell Chairman and CEO, Director | Feb 9, 2026 | Sale(10b5-1 plan) | −4,991 | $273.78 | $1.37M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | Feb 9, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Michael J. Rider Global General Counsel | Feb 4, 2026 | Sale(10b5-1 plan) | −50 | $260.00 | $13.00K | 9,691 |
| Peter C. Farrell Director | Feb 4, 2026 | Sale(10b5-1 plan) | −2,000 | $251.31 | $502.62K | 64,773 |
| Brett Sandercock Chief Financial Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −1,000 | $257.03 | $257.03K | 85,495 |
| Peter C. Farrell Director | Jan 7, 2026 | Sale(10b5-1 plan) | −2,000 | $248.83 | $497.66K | 66,773 |
| Michael J. Farrell Chairman and CEO, Director | Jan 7, 2026 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Michael J. Farrell Chairman and CEO, Director | Jan 7, 2026 | Sale(10b5-1 plan) | −4,991 | $248.46 | $1.24M | 466,223 |
| Michael J. Rider Global General Counsel | Jan 2, 2026 | Sale(10b5-1 plan) | −50 | $241.75 | $12.09K | 9,741 |
| Brett Sandercock Chief Financial Officer | Jan 2, 2026 | Sale(10b5-1 plan) | −1,000 | $241.75 | $241.75K | 86,495 |
| Michael J. Farrell Chairman and CEO, Director | Dec 8, 2025 | Sale(10b5-1 plan) | −4,991 | $251.41 | $1.25M | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | Dec 8, 2025 | Option exercise | +4,991 | $146.34 | $730.38K | 471,214 |
| Peter C. Farrell Director | Dec 3, 2025 | Sale(10b5-1 plan) | −2,000 | $251.47 | $502.94K | 68,773 |
| Michael J. Rider Global General Counsel | Dec 1, 2025 | Sale(10b5-1 plan) | −50 | $244.16 | $12.21K | 9,791 |
| Brett Sandercock Chief Financial Officer | Dec 1, 2025 | Sale(10b5-1 plan) | −1,000 | $244.16 | $244.16K | 87,495 |
| Witte Jan De Director | Nov 25, 2025 | Sale(10b5-1 plan) | −2,055 | $255.00 | $524.03K | 4,261 |
| Christopher DelOrefice Director | Nov 20, 2025 | Award | +1,073 | – | – | 2,423 |
| Ronald R. Taylor Director | Nov 20, 2025 | Award | +1,073 | – | – | 24,771 |
| Witte Jan De Director | Nov 20, 2025 | Award | +1,073 | – | – | 6,316 |
| Brett Sandercock Chief Financial Officer | Nov 20, 2025 | Award | +2,710 | – | – | 88,495 |
| Michael J. Farrell Chairman and CEO, Director | Nov 20, 2025 | Tax withholding | −7,297 | – | – | 466,223 |
| Michael J. Farrell Chairman and CEO, Director | Nov 20, 2025 | Award | +13,551 | – | – | 473,520 |
| Peter C. Farrell Director | Nov 20, 2025 | Award | +536 | – | – | 70,773 |
| Nicole Mowad-Nassar Director | Nov 20, 2025 | Award | +536 | – | – | 777 |
| John Hernandez Director | Nov 20, 2025 | Award | +1,073 | – | – | 5,118 |
| Desney Tan Director | Nov 20, 2025 | Award | +1,073 | – | – | 6,002 |
| Harjit Gill Director | Nov 20, 2025 | Award | +1,073 | – | – | 10,940 |
| Justin Leong Chief Product Officer | Nov 20, 2025 | Award | +1,848 | – | – | 29,028 |
| Carol Burt Director | Nov 20, 2025 | Award | +1,073 | – | – | 2,156 |
| Karen Drexler Director | Nov 20, 2025 | Award | +1,073 | – | – | 10,602 |
| Peter C. Farrell Director | Nov 14, 2025 | Tax withholding | −7,314 | $244.46 | $1.79M | 70,238 |
| Peter C. Farrell Director | Nov 14, 2025 | Option exercise | +11,442 | $101.64 | $1.16M | 77,552 |
| Peter C. Farrell Director | Nov 12, 2025 | Sale(10b5-1 plan) | −2,000 | $252.05 | $504.10K | 66,110 |
| Harjit Gill Director | Nov 11, 2025 | Tax withholding | −38.21 | $250.10 | $9.56K | 9,867 |
| Peter C. Farrell Director | Nov 11, 2025 | Tax withholding | −162.95 | $250.10 | $40.75K | 68,110 |
| Witte Jan De Director | Nov 11, 2025 | Sale(10b5-1 plan) | −487 | $250.25 | $121.87K | 5,319 |
| Witte Jan De Director | Nov 11, 2025 | Tax withholding | −76.45 | $250.10 | $19.12K | 5,242 |
| Michael J. Farrell Chairman and CEO, Director | Nov 11, 2025 | Tax withholding | −2,205.7 | $250.10 | $551.65K | 459,969 |
| Michael J. Farrell Chairman and CEO, Director | Nov 11, 2025 | Tax withholding | −2,231.55 | $250.10 | $558.11K | 465,634 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 15, 2026 (FINRA, reported twice a month)
Short % of shares outstanding
–
0M shares short
Days to cover
1000.0
At 0M shares a day
Change since last report
-63.4%
From 0M shares
Short volume, 0 days
–
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ResMed's stock actually held short. No settlement fails above the SEC's reporting threshold in the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Michael J. Farrell Officer, Director | Oct 7, 2026 | 4,991 | $1.13M | Oct 7, 2026 | Stock Option Exercise |
| Michael J. Farrell Officer, Director | Sep 8, 2026 | 4,991 | $1.13M | Sep 8, 2026 | Stock Option Exercise |
| Peter C. Farrell Director | Sep 2, 2026 | 970 | $227.61K | Sep 2, 2026 | Stock Option |
| Michael J. Farrell Officer, Director | Aug 7, 2026 | 4,991 | $1.03M | Aug 7, 2026 | Stock Option Exercise |
| Peter C. Farrell Director | Aug 5, 2026 | 8,000 | $1.80M | Aug 5, 2026 | Stock Option |
| Michael J. Farrell Officer, Director | Jul 7, 2026 | 4,991 | $1.09M | Jul 7, 2026 | Stock Option Exercise |
| Michael J. Farrell Officer, Director | Jun 8, 2026 | 4,991 | $968.25K | Jun 8, 2026 | Stock Option Exercise |
| Brett Sandercock Former Officer | May 27, 2026 | 8,000 | $1.67M | May 27, 2026 | Restricted Stock Vesting |
| Michael J. Farrell Officer, Director | May 7, 2026 | 4,991 | $1.04M | May 7, 2026 | Option Granted - 11/21/2019 |
| Michael J. Farrell Officer, Director | Apr 7, 2026 | 4,991 | $1.13M | Apr 7, 2026 | Option Granted - 11/21/2019 |
| Brett Sandercock Officer | Apr 1, 2026 | 1,000 | $224.31K | Apr 1, 2026 | Restricted Stock Vesting |
| Peter C. Farrell Director | Apr 1, 2026 | 2,000 | $449.92K | Apr 1, 2026 | Stock Option |
| Michael J. Farrell Officer, Director | Mar 9, 2026 | 4,991 | $1.25M | Mar 9, 2026 | Options Granted 11/21/2019 |
| Peter C. Farrell Director | Mar 4, 2026 | 2,000 | $520.36K | Mar 4, 2026 | Stock Option |
| Brett Sandercock Officer | Mar 2, 2026 | 1,000 | $254.30K | Mar 2, 2026 | Restricted Stock Vesting |